Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yervoy
Biotech
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Bristol Myers Squibb is walking away from CytomX's potential successor to Yervoy and wiping $300 million off the value of the alliance in the process.
Nick Paul Taylor
Mar 12, 2024 7:07am
Ultimovacs links BMS-cancer vaccine combo to improved survival
Oct 18, 2023 8:40am
Long survival spurs Ultimovacs to mull ways to end cancer trial
Aug 22, 2023 10:00am
PD-1 R&D tapers off as new molecules capture interest: IQVIA
May 24, 2023 2:09pm
Jounce gets trounced as phase 2 data disappoint once again
Aug 31, 2022 7:30am
BMS melanoma, genitourinary commercial lead heads to miR
Aug 13, 2021 9:45am